Immunotherapy targeting misfolded proteins in neurodegenerative disease

Brain and Nerve

Volumn 65, Issue 4, 2013, Pages 469-474

  Kanemaru, Kazutomi ^a  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Antibody; Immunotherapy; Misfolded protein; Neurodegenerative disease; Seeded aggregation

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; PROTEIN SOD1; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; HUNTINGTON CHOREA; IMMUNOTHERAPY; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 84876342410     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999 (Pubitemid 29327547)
2. Sc. J Neurosci 32: 8817-8830, 2012
3. Dementia Japan 27: 45-53, 2013
4. Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M: Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of neurodegenerative disease. J Biol Chem 285: 34885-34898, 2010
5. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al: Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11: 909-913, 2009
6. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30: 16559-16566, 2010
7. Maroteaux L, Campanelli JT, Scheller RH: Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8: 2804-2815, 1988
8. Jakes R, Spillantini MG, Goedert M: Identification of two distinct synucleins from human brain. FEBS Lett 345: 27-32, 1994 (Pubitemid 24154659)
9. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997 (Pubitemid 27443610)
10. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al: Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868, 2005 (Pubitemid 40805347)
11. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, et al: Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32: 13454-13469, 2012
12. Schneeberger A, Mandler M, Mattner F, Schmidt VV: Vaccination for Parkinson's disease. Parkinsonism Relat Disord 18 (Suppl 1): S11-S13, 2012
13. Ido A, Fukuyama H, Urushitani M: Protein misdirection inside and outside motor neurons in amyotrophic lateral sclerosis (ALS): a possible clue for therapeutic strategies. Int J Mol Sci 12: 6980-7003, 2011
14. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, et al: Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 9: 108-118, 2006 (Pubitemid 43011916)
15. Urushitani M, Ezzi SA, Julien JP: Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 104: 2495-2500, 2007 (Pubitemid 46391424)
16. Gros-Louis F, Soucy G, Lariviere R, Julien JP: Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 113: 1188-1199, 2010
17. Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N: A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem 286: 18664-18672, 2011
18. Wolfgang WJ, Miller TW, Webstar JM, Huston JS, Thompson LM, et al: Suppresion of Huntington's disease pathology in drosophia by human single-chain Fv antibodies. Proc Natl Acad Sci U S A 102: 11563-11568, 2005 (Pubitemid 41153859)
19. Miller TW, Messer A: Intrabody applications in neurological disorders: progress and future prospects. Molecular Therapy 12: 394-401, 2005 (Pubitemid 41158094)
20. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, et al: Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 11: 219-225, 2009